2022-500790-14-00招募中2 期
An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults with Primary Sclerosing Cholangitis (PSC)
Albireo AB, Albireo AB, Albireo AB8 个研究点 分布在 4 个国家目标入组 26 人开始时间: 2022年12月15日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 26
- 试验地点
- 8
- 主要终点
- The primary endpoint is safety and tolerability as determined by the incidence of treatment-emergent adverse events (TEAEs) through Week 12
研究概览
简要总结
To evaluate the safety and tolerability of A3907 in patients with PSC with and without a Clinically Relevant Stricture (CRS)
研究设计
- 分配方式
- Not Applicable
- 主要目的
- An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokineti
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Adults between 18 and 75 years of age (inclusive).
- •Have a clinical diagnosis of large-duct PSC with evidence of more than 6 months duration with either a consistent magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP) showing sclerosing cholangitis and historical evidence of elevated alkaline phosphatase (ALP).
- •Willing to sign informed consent.
- •Women of childbearing potential (WOCBP) and males with female partners of childbearing potential must agree to use contraception as detailed in Section 9.3.
- •Women of nonchildbearing potential (WONCBP) must meet the definition in Section 9.3.18 and have a confirmatory follicle stimulating hormone [FSH] level ≥ 40 mIU/mL .
- •Alkaline Phosphatase (ALP) value > 1.5 × upper limit of normal (ULN) but ≤ 10 ×ULN at Visit 1 (Screening Period). Before starting 12 weeks treatment variability of < 30% between ALP values at Visit 1 and Visit 2 must be confirmed. If variability is > 30 % a third ALP value may be obtained. If the third ALP value meets >1.5 × ULN but ≤ 10 × ULN the patient can start the 12-week treatment period.
- •Arms 1-3 Only: Total bilirubin < 1.5 × ULN (unless due to Gilberts Syndrome or hemolysis) and normal direct bilirubin.
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN
- •Serum bile acid level > ULN
- •Arms 1 - 3 Only: An MRCP or equivalent imaging modality performed within 6 months before the Screening Period that is consistent with PSC without a clinically relevant stricture.
- •Arm 4 Only: An MRCP or equivalent imaging modality performed within 6 months before the Screening Period that is consistent with PSC with a clinically relevant stricture, or clinically relevant bile duct obstruction (see Inclusion # 12 for additional information).
- •Use of ursodeoxycholic acid (UDCA) with a total daily dose ≤ 23 mg/kg/day, or bile acid-binding resins are permitted, with a minimum of 3 months of stable treatment prior to the Screening Period, and expected to remain on a stable dose through the 12-week treatment period; or a minimum of 3 months off UDCA prior to the Screening Period if UDCA was recently discontinued.
- •If a patient has inflammatory bowel disease (IBD) with a minimum disease duration of 4 weeks, this diagnosis should be documented. Inflammatory bowel disease should be in clinical remission or mildly active according to Crohn’s Disease Activity Index (CDAI), partial Mayo score for Crohn’s Disease (CD) and ulcerative colitis (UC), respectively (i.e., patients with CDAI score < 220 and Mayo score < 5, respectively). Patients with IBD should have had a colonoscopy performed within one year prior to the Screening Period with results showing no evidence of dysplasia or cancer.
- •Clinically stable for at least 3 months prior to the Screening Period.
- •Arm 4 Only: One stable clinically relevant biliary stricture of at least 4 weeks duration on contrast enhanced MRI/MRCP with > 75% reduction of duct diameter in the common bile duct or hepatic duct without suspicion of cholangiocarcinoma (further established by imaging and stable CA 19-9 below ULN repeated twice over 1 month), or cholelithiasis. Subjects may have signs or symptoms of worsening obstructive cholestasis (increasing jaundice, nausea, anorexia, steatorrhea and worsening or new onset pruritus), deterioration of liver function (i.e., decreasing platelet count, increasing international normalized ratio [INR]) and/could be listed for liver transplantation due to their clinically relevant biliary stricture.
- •Arm 4 Only: MELD Score < 35
排除标准
- •Medical History -
- •Presence of documented secondary sclerosing cholangitis (such as ischemic cholangitis, recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis, surgical or blunt abdominal trauma, recurrent pyogenic cholangitis, choledocholithiasis, toxic sclerosing cholangitis due to chemical agents, or any other cause of secondary sclerosing cholangitis).
- •Biliary intervention within 3 months prior to study enrollment or planned.
- •Presence of alternative causes of chronic liver disease, including alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, autoimmune hepatitis, or active hepatitis B or C.
- •IBD with uncontrolled moderate to severe activity and/or on treatment with any immunosuppressive, immunomodulator, or biologic agent for treatment of IBD (i.e. azathioprine, 6 mercaptopurine, tacrolimus, methotrexate, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, ozanimod). Treatment with corticosteroids (including budesonide, budesonide MMX and beclomethasone) in the previous 4 weeks.
- •History of human immunodeficiency virus infection or any other known relevant infection (e.g., tuberculosis).
- •History of colostomy or colectomy.
- •History of malignancy, including hepatocellular carcinoma within the past 10 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated.
- •History of transplants, including liver transplantation, or currently on active transplantation list.
- •Current or a history of ascites, encephalopathy, or history of esophageal variceal bleeding.
- •Known or suspected overlapping clinical and histologic diagnosis of autoimmune hepatitis.
- •Small duct PSC (evidence of PSC on historical liver histology, with normal bile ducts on cholangiography).
- •Liver cirrhosis as assessed by any of the following: a. historical liver histology • suspected liver fibrosis, defined by liver stiffness measurement, assessed by FibroScan (FibroScan value > 14.4 kPa). b. signs and symptoms of hepatic decompensation (including, but not limited to, jaundice, ascites, variceal haemorrhage, and/or hepatic encephalopathy).
- •Are female of childbearing potential, including those who are pregnant or lactating
- •History of alcohol or substance abuse in the previous 2 years. Patients must agree to refrain from illicit drug (including marijuana) and alcohol use during the study
- •Hypersensitivity to investigational medicinal product (A3907) and excipients.
- •Presence of any contraindication for undergoing MRCP (e.g., pacemaker). Treatment -
- •Administration of medications that slow gastrointestinal motility (Section 8.6.2).
- •Treatment with rifampicin
- •Treatment with CYP3A4 substrates acetaminophen, codeine, ciclosporin (cyclosporin), diazepam, and erythromycin.
- •Treatment with vitamin D or fibrates, unless patient is on a stable dose ≥ 6 months prior to baseline.
- •Exposure to an investigational drug, biologic agent, or medical device within 30 days prior to Screening, or 5 half-lives of the study agent, whichever is longer. Laboratory Exclusions -
- •Platelet count < 150 000/mm
- •Albumin level < 3.0 g/dL.
- •International normalised ratio (INR) > 1.4 (the patient may be treated with vitamin K intravenously, and if INR is ≤ 1.4 at resampling, the patient may be enrolled).
- •Advanced renal disease (glomerular filtration rate [GFR] < 70 mL/min/1.73 m2 ) Miscellaneous -
- •Any other conditions or abnormalities which, in the opinion of the investigator (or designee), may compromise the safety of the patient or interfere with the patient participating in or completing the study.
结局指标
主要结局
The primary endpoint is safety and tolerability as determined by the incidence of treatment-emergent adverse events (TEAEs) through Week 12
The primary endpoint is safety and tolerability as determined by the incidence of treatment-emergent adverse events (TEAEs) through Week 12
次要结局
- • PK parameters for A3907 including, but not limited to, Cmax, and area under the plasma AUC • Change from Baseline to Week 12 in serum and urine individual and total bile acid levels • Change from baseline to Week 12 in liver transaminases (ALT and AST), GGT, ALP and total and direct bilirubin levels. • Change from Baseline to Week 12 in 7α-hydroxy-4-cholesten-3-one (C4)
研究者
Jan P. Mattsson
Scientific
Albireo AB
研究点 (8)
Loading locations...
相似试验
招募中
2 期
A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, bone marrow, lymph and lymphatic system.2024-519498-20-00Cellcentric Limited16
尚未招募
1 期
Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic AnemiaSevere Aplastic AnemiaNCT07297550Institute of Hematology & Blood Diseases Hospital, China42
招募中
2 期
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10
招募中
2 期
A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic DermatitisAtopic Dermatitis2024-511260-84-00Apogee Therapeutics Inc.154
已完成
1 期
A Clinical Study of RSS0343 in Healthy SubjectsNCT07289464Reistone Biopharma Company Limited48